Open Orphan, the Dublin-listed pharmaceutical services company run by Cathal Friel, has announced that its hVIVO subsidiary has signed a £5 million contract with a European biotechnology company.
Under the terms of the contract, the European biotech company will test its intravenous antiviral candidate using the Hvivo human challenge study model for respiratory syncytial virus , an illness which affects the respiratory tract of children and at-risk adults. In severe cases it can...
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: businessposthq - 🏆 8. / 71 続きを読む »
ソース: businessposthq - 🏆 8. / 71 続きを読む »